Aim: This study compared genetic aberrations in hematopoietic cells (HCs) and mesenchymal stem cells of myelodysplastic syndrome (MDS-MSCs) patients. Methods: We obtained chromosomes with aberrations from 22 patients with MDS and chromosomes from 7 healthy individuals. Chromosomal aberrations in both HCs and MSCs were identified using G-banding. We then performed DNA content analysis of the HCs and MSCs. Results: Cytogenetic aberrations were detected in HCs from 13 of the 22 MDS patients (59%). Chromosomal aberrations in MSCs were detected in 15 of the 22 MDS patients (68%). No chromosomal abnormalities were identified in MSCs of the 7 healthy volunteers. We demonstrate herein that MSCs have distinct genetic abnormalities compared to HCs from the same individual. We observed a random loss of chromosomal material in significant proportions of MSCs. A high proportion of random loss may be a marker of chromosomal instability of MDS-MSCs. However, two case results showed that HCs and MSCs have different altered structural changes. Conclusion: Our results suggest enhanced genetic susceptibility of these cells in MDS patients. Our data indicates that the genetic alterations in MSCs may constitute a particular biological mechanism of MDS pathogenesis.

Keywords:
Chromosomal aberration, Mesenchymal stem cell, Myelodysplastic syndrome
1.
Bernasconi P: Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions – a review. Br J Haematol 2008;142:695–708.
2.
Nolte F, Hofmann WK: Myelodysplastic syndromes: molecular pathogenesis and genomic changes. Ann Hematol 2008;87:777–795.
3.
Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, Scadden DT, Ma’ayan A, Enikolopov GN, Frenette PS: Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010;466:829–834.
4.
Pontikoglou C, Delorme B, Charbord P: Human bone marrow native mesenchymal stem cells. Regen Med 2008;3:731–741.
5.
Olney HJ, Le Beau MM: The cytogenetics of myelodysplastic syndromes. Best Pract Res Clin Haematol 2001;14:479–495.
6.
Marcondes AM, Ramakrishnan A, Deeg HJ: Myeloid malignancies and the marrow microenvironment: some recent studies in patients with MDS. Curr Cancer Ther Rev 2009;5:310–314.
7.
Tauro S, Hepburn MD, Peddie CM,Bowen DT, Pippard MJ: Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 2002;16:785–790.
8.
Kastrinaki MC, Pontikoglou C, Klaus M, Stavroulaki E, Pavlaki K, Papadaki HA: Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes. Curr Stem Cell Res Ther 2011;6:122–130.
9.
Sloand EM, Rezvani K: The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 2008;45:39–48.
10.
Flores-Figueroa E, Montesinos JJ, Flores-Guzmán P, Gutiérrez-Espíndola G, Arana-Trejo RM, Castillo-Medina S, Pérez-Cabrera A, Hernández-Estévez E, Arriaga L, Mayani H: Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. Leuk Res 2008;32:1407–1416.
11.
Hu G, Liu P, Feng J, Jin Y: A novel population of mesenchymal progenitors with hematopoietic potential originated from CD14 peripheral blood mononuclear cells.Int J Med Sci 2010;27;8:16–29.
12.
Waller EK, Olweus J, Lund-Johansen F, Huang S, Nguyen M, Guo GR, Terstappen L: The ‘common stem cell’ hypothesis reevaluated: human fetal bone marrow contains separate populations of hematopoietic and stromal progenitors. Blood 1995;1:85:2422–2435.
13.
Deeg HJ, Beckham C, Loken MR, Bryant E, Lesnikova M, Shulman HM, Gooley T: Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndromes. Leuk Lymphoma 2000;37:405–414.
14.
Flores-Figueroa E, Arana-Trejo RM, Gutiérrez-Espíndola G, Pérez-Cabrera A, Mayani H: Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. Leuk Res 2005;29:215–224.
15.
Blau O, Baldus CD, Hofmann WK, Thiel G, Nolte F, Burmeister T, Türkmen S, Benlasfer O, Schümann E, Sindram A, Molkentin M, Mundlos S, Keilholz U, Thiel E, Blau IW: Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 2011;118:5583–5592.
16.
Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143–147.
17.
Kastrinaki MC, Pontikoglou C, Klaus M, Stavroulaki E, Pavlaki K, Papadaki HA: Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes. Curr Stem Cell Res Ther 2011;6:122–130.
18.
Soenen-Cornu V, Tourino C, Bonnet ML, Guillier M, Flamant S, Kotb R, Bernheim A, Bourhis JH, Preudhomme C, Fenaux P, Turhan AG: Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short- and long-term hematopoiesis in vitro. Oncogene 2005;24:2441–2448.
19.
Soenen V, Kotb R, Bonnet ML, Guillier M, Flamant S, Kotb R, Bernheim A, Bourhis JH, Preudhomme C, Fenaux P, Turhan AG: Mesenchymal cells (MC) from patients with myelodysplastic syndromes (MDS) are devoid of cytogenetic abnormalities and support short and long-term hematopoiesis in vitro. Blood 2001;98(suppl 1):3041a.
20.
Das M, Chatterjee S, Basak P, Das P, Pereira JA, Dutta RK, Chaklader M, Chaudhuri S, Law S: The bone marrow stem stromal imbalance – a key feature of disease progression in case of myelodysplastic mouse model. J Stem Cells 2010;5:49–64.
21.
Roobrouck VD, Clavel C, Jacobs SA, Ulloa-Montoya F, Crippa S, Sohni A, Roberts SJ, Luyten FP, Van Gool SW, Sampaolesi M, Delforge M, Luttun A, Verfaillie CM: Differentiation potential of human postnatal mesenchymal stem cells, mesoangioblasts, and multipotent adult progenitor cells reflected in their transcriptome and partially influenced by the culture conditions. Stem Cells 2011;29:871–882.
22.
Chen HT, Lee MJ, Chen CH, Chuang SC, Chang LF, Ho ML, Hung SH, Fu YC, Wang YH, Wang HI, Wang GJ, Kang L, Chang JK: Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. J Cell Mol Med 2012;16:582–593.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.